Humana Inc, the significant health insurer, has been facing an oscillating scenario. The company has been supporting reforms for
Medicare Advantage billing practices in line with UnitedHealth, causing a stir in the market. The recent investigation by
Edelson Lechtzin LLP Announces has also raised concerns. Substantial losses for investors and an increase in Medicare Advantage Home Visits have been predicted.
HUM shares have been sold by Wealth Enhancement Advisory Services. On a brighter note, an 'Outperform' rating has been reiterated for
Humana (HUM) by Bernstein SocGen Group and implied volatility is making it a viable investment choice. The companyβs
EPS guidance for 2025 has been reaffirmed amidst Medicare Advantage audits and a dip in the stock price. In recent weeks, Medicare-related activities have affected HUM's stock prices, leading to fluctuations. Although the stock has fallen after its earnings report, the company has outlined a promising margin expansion and strategic shifts in Q1.
HUM has also entered into new agreements for Value-Based Oncology Care, and revenues recorded an increase in the first quarter earnings to
US$32,112 Million.
Humana HUM News Analytics from Wed, 02 Oct 2024 07:00:00 GMT to Sat, 07 Jun 2025 08:03:35 GMT -
Rating 0
- Innovation -5
- Information 10
- Rumor 0
